logo-loader
viewInnoCan Pharma

InnoCan Pharma prices previously announced C$10 million offering

The firm said it will use the cash to fund research and product development costs, sales, marketing and operating expenses

InnoCan Pharma -
The offer is being led by Mackie Research Capital, as sole bookrunner, and Canaccord Genuity as co-lead agents, together with Haywood Securities Inc and PI Financial Corp

InnoCan Pharma Corporation (CSE:INNO) has now priced its previously announced C$10 million offering at C$0.20 a unit.

As reported on May 12 this year, the company said it will use the cash to fund research and product development costs, sales, marketing and operating expenses. It will also be used for working capital and general corporate purposes.

READ: InnoCan Pharma Corp unveils plans to raise up to C$10 million 

Each unit consists of one company share and one share purchase warrant. Each warrant is exercisable into one company share at C$0.25 for 36 months following completion of the offer.

InnoCan Pharma is a specialty pharma, which develops products that harness the properties of cannabinoids combined with smart delivery formulations.

The offer is being led by Mackie Research Capital, as sole bookrunner, and Canaccord Genuity as co-lead agents, together with Haywood Securities Inc and PI Financial Corp.

InnoCan has also granted its agents an option to cover over-allotments and for market stabilization purposes, exercisable in whole or in part at any time up to 30 days from the closing, to increase the size of offering by up to 15% of the number of units sold.

The closing of the offering is currently expected to be on or about the week of May 28.

Contact the author at [email protected]

Quick facts: InnoCan Pharma

Price: 0.23 CAD

CSE:INNO
Market: CSE
Market Cap: $33.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Innocan Pharma launches Derma CBD line in Europe

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has launched their CBD derma line. Bincovich discusses where it is being made and the first areas of the world it is being rolled out to. Bincovich also told gave Proactive an update...

on 8/6/20

2 min read